# Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects

> **NCT00522236** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 56 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008

## Key facts

- **NCT ID:** NCT00522236
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2012-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522236, "Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00522236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*